Germany is suspending routine use of the Oxford-AstraZeneca COVID-19 vaccine for people aged below 60.
This is due to risk of rare blood clots.
The German medicines regulator found 31 cases of a type of rare blood clot among the nearly 2.7 million people who had received the vaccine in Germany.
Canada earlier suspended use of the AstraZeneca jab in people under 55.
AstraZeneca said international regulators had found the benefits of its jab outweighed risks significantly.
It said it was continuing to analyses its database to understand “whether these very rare cases of blood clots associated with thrombocytopenia occur any more commonly than would be expected naturally in a population of millions of people”.
“We will continue to work with German authorities to address any questions they may have,” it added.
